OS Therapies Inc

OS Therapies Incorporated is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments for osteosarcoma and other solid tumors. Its pipeline features two core technologies: OST-HER2, an off-the-shelf immunotherapy utilizing an attenuated strain of Listeria monocytogenes to stimulate an immune response against HER2-expressing cancer cells, and a preclinical tunable antibody-drug conjugate platform known as OST-tADC. Beyond human oncology indications such as pediatric osteosarcoma, breast, lung, and esophageal cancers, the company explores veterinary applications in canines. Its intended patient populations include children, young adults, and older patients diagnosed with bone and solid cancers.

The company operates clinical development programs across major hospitals in the United States, including a completed Phase IIb trial conducted across 21 clinical sites in 18 U.S. states. Preclinical research collaborations extend internationally to contract research facilities in Bangalore, India. OS Therapies Incorporated maintains its principal executive offices in Grasonville, Maryland.

Summary of the business section of OS Therapies's latest annual report, written by StockData.

“of Osteosarcoma is approximately 1,000 individuals annually in the United States and approximately 20,000 globally.”